Get the Stockscreener App
0.357
6.27%
-0.0239
Pre-market:
.37
0.013
+3.64%
Lexicon Pharmaceuticals Inc stock is traded at $0.357, with a volume of 5.22M.
It is down -6.27% in the last 24 hours and down -51.84% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
See More
Previous Close:
$0.3809
Open:
$0.3745
24h Volume:
5.22M
Relative Volume:
0.84
Market Cap:
$129.05M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-0.4463
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-2.91%
1M Performance:
-51.84%
6M Performance:
-79.00%
1Y Performance:
-85.60%
1-Day Range:
$0.325
$0.38
1-Week Range:
$0.3228
$0.4089
52-Week Range:
$0.2836
$2.62
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
0.357 | 129.05M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Piper Sandler Cuts Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target to $6.00 - Defense World
Equities Analysts Issue Forecasts for LXRX Q1 Earnings - Defense World
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus PT from Brokerages - Defense World
Lexicon Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies - TipRanks
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges - TipRanks
LEXICON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
What Analysts Are Saying About Lexicon Pharmaceuticals Stock - Benzinga
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlig - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lexicon Pharmaceuticals Advances Pipeline Amid Financial Growth - TipRanks
Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com India
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Lexicon: Q4 Earnings Snapshot - KTEN
Lexicon Pharma beats Q4 estimates, shares rise on strong revenue - Investing.com India
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharma beats Q4 estimates, shares rise on strong revenue By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
Can Lexicon's 38x Revenue Growth and Pain Drug Success Transform Its Future? - StockTitan
Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2 - Marketscreener.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Market Perform” Rating at Leerink Partners - Defense World
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - The Manila Times
Lexicon Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Nasdaq
When Will Lexicon Pharmaceuticals Reveal Its 2024 Financial Performance? - StockTitan
Private equity firms who have a significant stake must be disappointed along with institutions after Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap dropped by US$148m - Simply Wall St
Lexicon’s Sunny Take Does Not Sway Investors About Phase IIb DPNP Miss - News & Insights
Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On? - Benzinga
Lexicon Says Pilavapadin Showed 'Meaningful' Pain Reduction But Results Miss Primary Endpoint - Marketscreener.com
Lexicon Pharmaceuticals stock tumbles after clinical study results By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals stock tumbles after clinical study results - Investing.com India
Lexicon advances pilavapadin into Phase 3 for diabetic pain - Investing.com India
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times
Lexicon advances pilavapadin into Phase 3 for diabetic pain By Investing.com - Investing.com South Africa
Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study - StreetInsider.com
Can Lexicon's Non-Opioid Pain Drug Break 20-Year Innovation Drought? Phase 2b Results Reveal Path Forward - StockTitan
Lexicon Pharma To Announce Topline Results From Phase 2b PROGRESS Study Today - Nasdaq
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times
Lexicon Pharmaceuticals to Host Conference Call on Phase 2b Results for Pilavapadin in Diabetic Peripheral Neuropathic Pain - Nasdaq
Can Lexicon's Non-Opioid Drug Transform Diabetic Pain Treatment? Phase 2b Results Coming - StockTitan
Lexicon Pharmaceuticals, Inc. Announces Resignation of Praveen Tyle as Executive Vice President, Research and Development, Effective as of April 26, 2021 - Marketscreener.com
Lexicon to cut 50% of workforce to focus on sotagliflozin - MSN
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) - Yahoo Finance
Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain - News & Insights
Merck: 4 No-Brainer Reasons to Buy This Dip - The Globe and Mail
Vantage Markets Partners with Scuderia Ferrari HP for a Multi-Year Sponsorship - The Globe and Mail
Peripheral Neuropathic Pain Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Grünenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith - Barchart
Peripheral Neuropathic Pain Market to Show Remarkable Growth - openPR
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):